Epstein Barr Virus (EBV) - Epidemiology Forecast - 2032

DelveInsight's 'Epstein-Barr Virus - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Epstein-Barr Virus in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.

Epstein-Barr Virus: Disease Understanding

Epstein-Barr Virus Overview

Epstein-Barr Virus (EBV) is a common virus that remains dormant in most people. EBV causes infectious mononucleosis (IM) and has been associated with certain cancers, including Burkitt lymphoma, immunoblastic lymphoma, nasopharyngeal cancer, and stomach (gastric) cancer.

The transmission of EBV occurs in several ways, such as deep kissing or food-sharing. Increased levels of viral DNA are found in salivary secretions after the initial infection. Children can be infected after eating food that an EBV-infected individual has already chewed. The transmission has occurred through stem cells, organ transplantation, and blood transfusion.

The clinical presentation of the EBV infection usually overlaps with other acute viral syndromes caused by other viruses, such as cytomegalovirus (CMV) and hepatitis viruses, which can lead to similar symptoms. Diagnostic schemes of EBV differ according to the patient's immune condition because the importance and urgency of therapeutic intervention differ between immunocompromised and immunocompetent individuals; a wide range of assays was utilized in diagnosing EBS.

Therapeutic strategies include prophylaxis, preemptive therapy, and targeted therapy. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-cell therapy are recommended as first-line therapy, whilst unselected donor lymphocyte infusions or chemotherapy are options as second-line therapy; other methods, including antiviral drugs, are discouraged.

Epidemiology

The Epstein-Barr Virus epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Epstein-Barr Virus epidemiology segmented as the Diagnosed Incident Cases of Epstein-Barr Virus IM, Incident Cases of Epstein-Barr Virus + Cancer, Incident cases of Epstein-Barr Virus + PTLD. The report includes the total Epstein-Barr Virus cases in the 7MM covering the United States, EU4 and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Epstein-Barr Virus Epidemiology

The epidemiology segment also provides the Epstein-Barr Virus epidemiology data and findings across the United States, EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

The total number of Epstein-Barr Virus IM cases in the 7MM countries was more than 1,120,000 in 2021.

As per the estimates, the United States had the highest number of incident cases of Epstein-Barr Virus in 2021. Among EU4 and the UK, Germany had the highest number of Epstein-Barr Virus cases, with more than 146,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of Epstein-Barr Virus cases, with close to 79,000 cases in 2021.

Scope of the Report:

• Epstein-Barr Virus report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Epstein-Barr Virus epidemiology report and model provide an overview of the risk factors and global trends of Epstein-Barr Virus in the seven major markets (The 7MM: The US, France, Germany, Italy, Spain, the UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Epstein-Barr Virus in seven major markets covering the US, EU4 and the UK, and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Epstein-Barr Virus.
• The report provides the segmentation of the Epstein-Barr Virus epidemiology by the diagnosed prevalent cases of Epstein-Barr Virus, mutation-specific cases of Epstein-Barr Virus, and comorbidity associated with Epstein-Barr Virus in the 7MM.

Report Highlights:

• 11-year Forecast of Epstein-Barr Virus Epidemiology
• The 7MM Coverage
• Diagnosed prevalent cases of Epstein-Barr Virus
• Mutation-specific cases of Epstein-Barr Virus
• Comorbidity associated with Epstein-Barr Virus

KOL Views

We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, which will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in an indication of Epstein-Barr Virus during the forecast period (2019-2032)?
• What key findings about Epstein-Barr Virus epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of Epstein-Barr Virus patients across the 7MM forecast period (2019-2032)?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of Epstein-Barr Virus?
• What currently available treatments for Epstein-Barr Virus?

Reasons to buy:

Epstein-Barr Virus epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Epstein-Barr Virus market.
• Quantify patient populations in the global Epstein-Barr Virus market to improve product design, pricing, and launch plans.
• Understand the magnitude of the Epstein-Barr Virus population by its diagnosed prevalent cases, mutation-specific cases, and comorbidity associated with Epstein-Barr Virus.
• The Epstein-Barr Virus epidemiology report and model were written and developed by Masters and PhD epidemiologists.
• The Epstein-Barr Virus epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 and the United Kingdom
• Japan

Study Period: 2019-2032